Marinus Pharmaceuticals (NASDAQ:MRNS) was downgraded by research analysts at BidaskClub from a “buy” rating to a “hold” rating in a note issued to investors on Monday, October 15th.
Other equities analysts also recently issued research reports about the stock. Mizuho reaffirmed a “buy” rating and issued a $13.00 price objective on shares of Marinus Pharmaceuticals in a report on Tuesday, September 25th. Cantor Fitzgerald set a $19.00 price target on shares of Marinus Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, September 25th. Zacks Investment Research raised shares of Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, October 10th. Finally, ValuEngine downgraded shares of Marinus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, October 6th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the stock. Marinus Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $19.67.
Shares of MRNS traded down $0.02 during mid-day trading on Monday, reaching $5.31. 441,232 shares of the stock traded hands, compared to its average volume of 842,646. Marinus Pharmaceuticals has a 12-month low of $3.31 and a 12-month high of $10.54. The firm has a market capitalization of $214.78 million, a P/E ratio of -6.64 and a beta of 3.20.
Several hedge funds and other institutional investors have recently modified their holdings of MRNS. BlackRock Inc. raised its position in Marinus Pharmaceuticals by 9.8% in the third quarter. BlackRock Inc. now owns 2,910,405 shares of the biopharmaceutical company’s stock worth $29,103,000 after acquiring an additional 259,793 shares in the last quarter. Jennison Associates LLC raised its position in Marinus Pharmaceuticals by 0.8% in the second quarter. Jennison Associates LLC now owns 2,757,356 shares of the biopharmaceutical company’s stock worth $19,495,000 after acquiring an additional 21,733 shares in the last quarter. Northern Trust Corp raised its position in Marinus Pharmaceuticals by 625.7% in the second quarter. Northern Trust Corp now owns 386,864 shares of the biopharmaceutical company’s stock worth $2,736,000 after acquiring an additional 333,555 shares in the last quarter. VHCP Management II LLC bought a new stake in Marinus Pharmaceuticals in the second quarter worth about $2,441,000. Finally, Fosun International Ltd bought a new stake in Marinus Pharmaceuticals in the third quarter worth about $1,446,000. Institutional investors and hedge funds own 63.71% of the company’s stock.
About Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical stage product candidate, ganaxolone, is an allosteric modulator of GABAA, developed in three different dose forms: intravenous (IV), capsule, and liquid.
See Also: How to Use a Moving Average for Trading
Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.